Volume 11, Issue 4 (2023)                   Health Educ Health Promot 2023, 11(4): 609-614 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Panahi Y, Sadeghi Ghahroudi M, Hosseinjani E. Efficacy and Safety of Nanocurcumin in Patients with Heart Failure Reduced Ejection Fraction; A Randomized Placebo-Controlled Clinical Trial. Health Educ Health Promot 2023; 11 (4) :609-614
URL: http://hehp.modares.ac.ir/article-5-71033-en.html
1- Pharmacotherapy Department, School of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran
2- Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- “Department of Cardiology, School of Medicine” and “Shahid Labbafinezhad Hospital”, Shahid Beheshti University of Medical Sciences, Tehran Iran
Abstract:   (275 Views)
Aims: Heart failure reduced ejection fraction (HFrEF) is defined as symptoms, such as shortness of breath and edema with an ejection fraction of less than 40% in echocardiography. Regarding the pathogenesis, the role of inflammation is undeniable. Interleukin 6 (IL-6) is one of the pro-inflammatory cytokines that is important in cardiovascular disease and has a critical role in CAD. It is also related to complications caused by heart failure and mortality. Nanocurcumin is a polyphenol extracted from the rhizome of Curcuma longa (turmeric) with better bioavailability. Effects of nanocurcumin on the reduction of IL-6 and NT-proBNP in hospitalized HFrEF patients with acute decompensation were investigated.
Materials & Methods: Sixty patients with HFrEF admitted with acute heart failure were divided into the intervention group with the administration of 40 mg of nanocurcumin twice a day for seven days and the control group (placebo). The levels of electrolytes, creatinine, IL-6, and NT-proBNP were measured at baseline and after one week.
Findings: There was no statistically significant difference in the reduction in IL-6 and NT-proBNP levels in the intervention and control groups (p>0.05). Also, there was no significant difference in creatinine and estimated glomerular filtration rate in the two groups (p>0.05).
Conclusion: Nanocurcumin at a dose of 40 mg twice a day for seven days in patients with acute decompensated heart failure did not reduce IL-6 and NT-proBNP levels.
Full-Text [PDF 670 kb]   (167 Downloads) |   |   Full-Text (HTML)  (7 Views)  
Article Type: Original Research | Subject: Health Care
Received: 2023/08/12 | Accepted: 2023/11/8 | Published: 2023/11/18
* Corresponding Author Address: Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Sheykh Bahaei Street, Tehran, Iran. Postal Code: - (sadeghimg@yahoo.com)

References
1. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230-9. [Link] [DOI:10.1002/ejhf.1149]
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-726. [Link] [DOI:10.1093/eurheartj/ehab368]
3. Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT, et al. Sex differences in new-onset heart failure. Clin Res Cardiol. 2015;104:342-50. [Link] [DOI:10.1007/s00392-014-0788-x]
4. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of Prevend. Eur Heart J. 2013;34(19):1424-31. [Link] [DOI:10.1093/eurheartj/eht066]
5. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of disease study 2017. Lancet. 2018;392(10159):1789-858. [Link] [DOI:10.1016/S0140-6736(18)32279-7]
6. Koh AS, Tay WT, Teng TH, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction. Eur J Heart Fail. 2017;19(12):1624-34. [Link] [DOI:10.1002/ejhf.945]
7. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Med. 2015;175(6):996-1004. [Link] [DOI:10.1001/jamainternmed.2015.0924]
8. Murphy SP, Kakkar R, McCarthy CP, Januzzi Jr JL. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324-40. [Link] [DOI:10.1016/j.jacc.2020.01.014]
9. Markousis‐Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, et al. The clinical significance of interleukin‐6 in heart failure: Results from the BIOSTAT‐CHF study. Eur J Heart Fail. 2019;21(8):965-73. [Link] [DOI:10.1002/ejhf.1482]
10. Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, Gencer MZ, Ammari A, Sadeghi A, et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol. 2020;89:107088. [Link] [DOI:10.1016/j.intimp.2020.107088]
11. Saeidinia A, Keihanian F, Butler AE, Bagheri RK, Atkin SL, Sahebkar A. Curcumin in heart failure: A choice for complementary therapy. Pharmacol Res. 2018;131:112-9. [Link] [DOI:10.1016/j.phrs.2018.03.009]
12. Karthikeyan A, Senthil N, Min T. Nanocurcumin: A promising candidate for therapeutic applications. Front Pharmacol. 2020;11:487. [Link] [DOI:10.3389/fphar.2020.00487]
13. Shaito A, Thuan DT, Phu HT, Nguyen TH, Hasan H, Halabi S, et al. Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety. Front Pharmacol. 2020;11:422. [Link] [DOI:10.3389/fphar.2020.00422]
14. Alherbish A, Charrois TL, Ackman ML, Tsuyuki RT, Ezekowitz JA. The prevalence of natural health product use in patients with acute cardiovascular disease. PLoS One. 2011;6(5):e19623. [Link] [DOI:10.1371/journal.pone.0019623]
15. Hatamipour M, Sahebkar A, Alavizadeh SH, Dorri M, Jaafari MR. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iran J Basic Med Sci. 2019;22(3):282. [Link]
16. McKechnie DG, Papacosta AO, Lennon LT, Welsh P, Whincup PH, Wannamethee SG. Inflammatory markers and incident heart failure in older men: The role of NT-proBNP. Biomark Med. 2021;15(6):413-25. [Link] [DOI:10.2217/bmm-2020-0669]
17. Dastani M, Bigdelu L, Hoseinzadeh M, Rahimi HR, Karimani A, Mohammadpour AH, et al. The effects of curcumin on the prevention of atrial and ventricular arrhythmias and heart failure in patients with unstable angina: A randomized clinical trial. Avicenna J Phytomed. 2019;9(1):1-9. [Link]
18. Alhashemi SH, Mohammadpour AH, Heidari R, Nikoo MH, Nemati MH, Vazin A. The effect of nanocurcumin on the incidence of atrial fibrillation, and markers of inflammation and oxidative stress level after coronary artery bypass graft surgery: A randomized, double-blind, placebo-controlled clinical study. Avicenna J Phytomed. 2022;12(5):503-13. [Link]
19. Dastani M, Rahimi HR, Askari VR, Jaafari MR, Jarahi L, Yadollahi A, et al. Three months of combination therapy with nano‐curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double‐blinded, placebo‐controlled clinical trial. Biofactors. 2023;49(1):108-18. [Link] [DOI:10.1002/biof.1874]
20. Saraf-Bank S, Ahmadi A, Paknahad Z, Maracy M, Nourian M. Effects of curcumin on cardiovascular risk factors in obese and overweight adolescent girls: A randomized clinical trial. Sao Paulo Med J. 2019;137:414-22. [Link] [DOI:10.1590/1516-3180.2018.0454120419]
21. Campbell MS, Ouyang A, Krishnakumar IM, Charnigo RJ, Westgate PM, Fleenor BS. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial. Nutrition. 2019;62:135-9. [Link] [DOI:10.1016/j.nut.2019.01.002]
22. Fakhri F, Shakeryan S, Fakhri S, Alizadeh A. The effect of 6 weeks of high intensity interval training (HIIT) with nano-curcumin supplementation on factors related to cardiovascular disease in inactive overweight girls. KAUMS J (FEYZ). 2020;24(2):181-9. [Persian] [Link] [DOI:10.18502/ijdo.v11i3.2606]
23. Samadian F, Dalili N, Gholi FP, Fattah M, Malih N, Nafar M, et al. Evaluation of Curcumin's effect on inflammation in hemodialysis patients. Clin Nutrition ESPEN. 2017;22:19-23. [Link] [DOI:10.1016/j.clnesp.2017.09.006]
24. Van Linthout S, Tschöpe C. Inflammation-cause or consequence of heart failure or both?. Curr Heart Fail Rep. 2017;14:251-65. [Link] [DOI:10.1007/s11897-017-0337-9]

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.